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Abstract SMAP-29 is a cathelicidin-derived peptide deduced
from sheep myeloid mRNA. The C-terminally amidated form of
this peptide was chemically synthesized and shown to exert a
potent antimicrobial activity. Antibiotic-resistant clinical isolates
highly susceptible to this peptide include MRSA and VREF
isolates, that are a major worldwide problem, and mucoid
Pseudomonas aeruginosa associated with chronic respiratory
inflammation in CF patients. In addition, SMAP-29 is also
active against fungi, including Cryptococcus neoformans isolated
from immunocompromised patients. SMAP-29 causes significant
morphological alterations of the bacterial surfaces, as shown by
scanning electron microscopy, and is also hemolytic against
human, but not sheep erythrocytes. Its potent antimicrobial
activity suggests that this peptide is an excellent candidate as a
lead compound for the development of novel antiinfective agents.
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1. Introduction
Gene-encoded antimicrobial peptides are a widespread
host-defense mechanism. A great number has been character-
ized in the last 15 years in animals, plants and bacteria [1^3].
Most of these peptides display a good selectivity for microbial
vs. host membranes. This is thought to result from di¡erences
in membrane composition, e.g. a high content of anionic
phospholipids on the surface of the bacterial cytoplasmic
membrane, presence of LPS in the outer membrane of
Gram-negative microorganisms, and lack of cholesterol in
bacterial membranes [4].
The protective function of antimicrobial peptides in host-
defense has been convincingly demonstrated in Drosophila,
where their reduced expression dramatically decreases survival
after microbial challenge [5,6]. In mammals, this function is
suggested by defective bacterial killing in the lung of cystic
¢brosis (CF) patients and in the small intestine of MAT3=3
mice. In CF patients this de¢cit is attributed to an abnormally
high salt concentration in the airway surface £uid that inhibits
the activity of L-defensin-1, an antimicrobial peptide ex-
pressed in human airway epithelial cells [7]. In MAT3=3
mice the defect in bacterial killing depends on lack of matri-
lysin, a metalloproteinase of the Paneth cells that cleaves in-
active procryptdins to active cryptdins, antimicrobial peptides
that are released in small intestine [8].
The antimicrobial peptides found in mammals belong to the
defensin (K- and L-defensins) and cathelicidin families. Pep-
tides of the latter family are highly diverse and are synthesized
at the C-terminus of precursors characterized by a conserved
prosequence [9,10].
cDNA cloning of novel members of this family in sheep led
to the identi¢cation of a putative peptide of 29 residues,
named SMAP-29 [11] or SC5 [12], with a C-terminal glycine
likely corresponding to an amidation signal. This highly cat-
ionic peptide was predicted to assume an amphipatic K-helical
conformation and a corresponding synthetic peptide was
shown to exert potent antimicrobial activity against a few
bacterial strains (Staphylococcus aureus, Pseudomonas aerugi-
nosa, Klebsiella pneumoniae) and fungi (Candida albicans) [12].
Although preliminary, these observations suggested a high
potency and broad spectrum of activity for this peptide.
In this study the structure and biological activities of
SMAP-29 have been extensively characterized. We show
that the peptide adopts an amphipatic K-helical conformation
and exerts a highly potent antimicrobial activity in vitro
against a broad spectrum of microorganisms, including anti-
biotic-resistant clinical isolates and fungi that cause serious
infections. SMAP-29 acts by rapidly permeabilizing bacterial
membranes and inducing remarkable changes in the surface
morphology of susceptible microorganisms. Interestingly, the
peptide is also hemolytic on human, but not sheep erythro-
cytes.
2. Materials and methods
2.1. Materials
PAL PEG-PS resin, coupling reagents for peptide synthesis and
Fmoc amino acids were purchased from PerSeptive Biosystems (Fra-
mingham, MA, USA). Anhydroscan-grade dimethylformamide, N-
methyl-2-pyrrolidone, dichloromethane and HPLC-grade acetonitrile
were from Lab-Scan (Dublin, Ireland). Tri£uoroacetic acid, N-meth-
ylmorpholine and tri£uoroethanol (TFE) were obtained from Acros
Chimica (Beerse, Belgium). Mueller-Hinton broth (MHB), yeast ex-
tract, agar, dextrose, bacteriological and mycological peptone were
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from Difco Laboratories (Detroit, MI, USA). Melittin and o-nitro-
phenyl-L-D-galactopyranoside were purchased from Sigma (St. Louis,
MO, USA) and PADAC from Calbiochem (La Jolla, CA, USA). All
other reagents were of analytical grade.
2.2. Peptide synthesis
SMAP-29 was synthesized as a 28 residue, C-terminally amidated
peptide by the solid phase method, using a Milligen 9050 synthesizer
and the Fmoc chemistry. As several couplings were predicted to be
di⁄cult, the synthesis was performed at 48‡C by heating the jacketed
column and the solvent solutions. For each coupling step, the Fmoc-
protected amino acid and coupling reagents were added in a 6- to
8-fold molar excess with respect to resin substitution. Couplings (30^
60 min) were carried out with N-hydroxybenzotriazole (HOBt) and 2-
(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium tetra£uoro-borate
(TBTU), except for residues 8^14 and 20^25, when the highly e⁄cient
acylating reagent O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluro-
nium hexa£uorophosphate (HATU) was used. Following Fmoc de-
protection and before addition of the following residue the resin was
washed for 15 min with a solution of dichloromethane/dimethylform-
amide/N-methyl-2-pyrrolidone (1:1:1) containing 1% Triton X-100
and 2 M ethylencarbonate (‘magic mixture’) [13]. Amino acid side-
chains were protected as follows: 2,2,5,7,8-pentamethylchroman-6-sul-
phonyl (Arg), t-butoxycarbonyl (Lys), trityl (His) and t-butyl (Tyr
and Thr). Cleavage from the resin and deprotection of the synthesized
peptide were carried out with a solution of 90% tri£uoroacetic acid,
3% water, 1% triisopropylsilane and 2% each of phenol, 1,2-ethane-
dithiol and thioanisole. After repeated precipitation with ether, the
peptide was puri¢ed by RP-HPLC on a C18 column (Delta-Pak,
Waters, Bedford, MA, USA), using an appropriate 0^60% acetonitrile
gradient in 0.1% tri£uoroacetic acid.
2.3. CD spectroscopy
CD measurements were performed at room temperature on a Jasco
J-600 spectropolarimeter, using 0.2 and 2 mm path length cells. Pep-
tide samples (¢nal concentration in the range 10^150 WM) were dis-
solved in 5 mM sodium phosphate bu¡er, pH 7.0, in the absence or
presence of 15, 30 and 45% TFE. The K-helical content was estimated
by using the equation [a]/[a]K, where [a] is the mean molar ellipticity
per residue at 222 nm, in ‡ cm2 dmol31, and [a]K the estimated molar
ellipticity for a 100% helical peptide given by 340 000(132.5/n), where
n is the number of residues in the peptide [14].
2.4. Antimicrobial and membrane-permeabilizing activities
The antimicrobial activity of SMAP-29 was evaluated by the broth
microdilution susceptibility test as previously described [15]. The ac-
tivity, expressed as minimum inhibitory concentration (MIC) and
minimum bactericidal concentration (MBC), was determined against
the following bacterial strains: Escherichia coli ATCC 25922, D21 and
ML-35, Salmonella typhimurium ATCC 14028, P. aeruginosa ATCC
27853 and two clinical isolates from CF patients, Serratia marcescens
ATCC 8100, Proteus vulgaris ATCC 13315, Bacillus megaterium
Bm11, Staphylococcus epidermidis ATCC 12228, S. aureus ATCC
25923, Cowan 1 and two methicillin-resistant clinical isolates
(MRSA), Enterococcus faecalis ATCC 29212 and a vancomycin-resis-
tant clinical isolate (VREF). The antifungal activity was evaluated
against clinical isolates of C. albicans, Cryptococcus neoformans and
Rhodotorula rubra.
The permeabilizing e¡ect of SMAP-29 on the outer and inner mem-
branes of the lactose permease de¢cient, L-galactosidase constitutive
E. coli ML-35 strain was evaluated as previously described [15], using
the normally impermeant substrates PADAC and o-nitrophenyl-L-D-
galactopyranoside for the periplasmic L-lactamase and cytoplasmic L-
galactosidase, respectively. Erythrocytes were prepared from freshly
collected, anticoagulated human or sheep blood. The assays were
performed in phosphate bu¡ered saline (PBS) by incubating 10%
(vol/vol) erythrocyte suspensions with various amounts of peptide
for 30 min at 37‡C. The reaction was stopped with cold PBS and,
after centrifugation at 10 000Ug for 1 min, the supernatant carefully
removed and the release of hemoglobin measured at 415 nm. The
percentage of hemolysis was determined as (Apep3Ablank)/
(Atot3Ablank)U100, where Ablank and Atot correspond respectively to
the hemolysis in the absence of the peptide and to 100% hemolysis as
obtained by addition of 0.2% Triton X-100. Melittin was used as a
positive control.
2.5. Scanning electron microscopy
Midlog phase E. coli ML-35 or methicillin-resistant S. aureus were
resuspended at 108 CFU/ml in 10 mM Na-phosphate bu¡er, pH 7.4,
supplemented with 100 mM NaCl (bu¡er A), and incubated at 37‡C
with SMAP-29. Controls were run in the presence of peptide solvent.
After 30 min the cells were ¢xed with an equal volume of 5% glutar-
aldehyde in 0.2 M Na-cacodylate bu¡er, pH 7.4. After ¢xation for 2 h
at 4‡C, the samples were ¢ltered on Isopore ¢lters (0.2 Wm pore size,
Millipore, Bedford, MA, USA) and extensively washed with 0.1 M
Na-cacodylate bu¡er, pH 7.4. The ¢lters were then treated with 1%
osmium tetroxide, washed with 5% sucrose in cacodylate bu¡er and
subsequently dehydrated with a graded ethanol series. After lyophili-
zation and gold coating, the samples were examined on a Leica Ster-
oscan 430i instrument (Leica Inc., Deer¢eld, IL, USA).
2.6. Analytical assays
Peptide concentration was determined by measuring the absorbance
of Tyr at 276 nm using an extinction coe⁄cient of 1450 M31 cm31.
The molecular mass of the puri¢ed peptide was determined with an
API I ion spray mass spectrometer (PE SCIEX, Toronto, Canada).
3. Results and discussion
3.1. Structural analysis of SMAP-29
SMAP-29 was chemically synthesized as a 28 residue pep-
tide (RGLRRLGRKIAHGVKKYGPTVLRIIRIA) amidated
at the C-terminus, as indicated by the presence of C-terminal
glycine, a common amidation signal in cathelicidin peptides
[9]. The correct peptide was obtained in greater than 60%
yield and with a measured mass of 3198.0 þ 0.3 vs. a calcu-
lated mass of 3197.99 Da, and was homogeneous after prep-
arative puri¢cation, as con¢rmed by mass and analytical RP-
HPLC.
Secondary structure prediction studies based on the PHD
pro¢le network indicate that SMAP-29 can assume an K-hel-
ical conformation in the region preceding Gly-18 and Pro-19.
Table 1
Antimicrobial activity of SMAP-29
Organism and strain MIC (WM)
E. coli ATCC 25922 0.25
E. coli ML-35 0.25
E. coli D21 0.12
S. typhimurium ATCC 14028 0.25
P. aeruginosa ATCC 27853 0.5
P. aeruginosa (isolate from FC patient) 0.25
P. aeruginosa (isolate from FC patient) 2.0
S. marcescens ATCC 8100 0.25
P. vulgaris ATCC 13315 s 80
S. aureus ATCC 25923 0.5
S. aureus Cowan 1 0.5
S. aureus (MRSA, clinical isolate) 1.0
S. aureus (MRSA, clinical isolate) 0.5
S. epidermidis ATCC 12228 0.25
E. faecalis ATCC 29212 1.0
E. faecalis (VREF, clinical isolate) 1.0
B. megaterium Bm11 0.25
C. albicans (clinical isolate) 4.0
C. neoformans (clinical isolate) 1.0
C. neoformans (clinical isolate) 1.0
C. neoformans (clinical isolate) 1.0
R. rubra 0.5
MIC was de¢ned as the lowest concentration of peptide preventing
visible growth after 18 h (bacteria) and 48 h (fungi) incubation at
37‡C. Bacteria and fungi were grown in Mueller-Hinton broth and
in Sabouraud, respectively. Results, determined with approximately
1.0^2.0U105 (bacteria) and 0.2^0.4U105 (fungi) colony forming
units/ml, are the mean of at least three independent determinations
with a divergence of not more than one MIC value.
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These residues likely form a loop followed by an extended and
highly hydrophobic C-terminal region, reminiscent of BMAP-
27 and -28 from cattle [16]. The predicted helix in the 1^18
region is amphipathic. This is suggested by the helical wheel
projection, that shows a striking segregation of polar and
non-polar residues, and by a high mean hydrophobic moment
per residue (W= 0.861) calculated according to Eisenberg [17].
This W value is one of the highest found in a comparative
analysis of a number of natural antimicrobial peptides [18]
and suggests a potent antimicrobial activity for SMAP-29.
The structural prediction has been con¢rmed by circular
dichroism. Spectra were recorded in 5 mM Na-phosphate
bu¡er at pH 7.0 in the absence or presence of increasing
amounts of the helix-inducing solvent TFE. CD spectra of
SMAP-29 in aqueous bu¡er are typical of an unordered con-
formation. Addition of TFE induces a transition to an K-
helical conformation with a helical content of 27.3, 51.5 and
57.6% at respectively 15, 30 and 45% (v/v) TFE (not shown).
The helical content did not increase at higher TFE concen-
trations. The existence of an isodichroic point at approxi-
mately 203 nm is consistent with a two-state helix-coil equilib-
rium. The concentration-dependence and in£uence of anions
on the conformation of SMAP-29 was investigated by record-
ing CD spectra in 5 mM Na-phosphate bu¡er, pH 7.0, at
peptide concentrations up to 150 WM, or at 40 WM in the
presence of 15 mM bicarbonate. In both cases the CD spectra
are typical of an unordered conformation, suggesting that
SMAP-29 is monomeric and does not self-associate into hel-
ical oligomers under these conditions. In contrast, other K-
helical peptides, e.g. human LL-37 and porcine PMAP-37,
may oligomerize and assume an K-helical conformation in
aqueous solution in an anion-, pH- and concentration-de-
pendent manner [19,20].
3.2. Antimicrobial activity
The in vitro antimicrobial activity of SMAP-29 was de-
termined as MIC and MBC values. A wide panel of Gram-
negative and Gram-positive bacteria and of fungi was
used, including clinical isolates of MRSA, VREF, mucoid
Fig. 1. Kinetics of permeabilization of E. coli ML-35 outer and in-
ner membranes by SMAP-29. Permeabilization was determined spec-
trophotometrically by following the unmasking of the periplasmic L-
lactamase (OM permeabilization) and the cytoplasmic L-galactosi-
dase (IM permeabilization) activities. Each assay was performed
with approximately 107 colony forming units/ml in 10 mM sodium
phosphate bu¡er, pH 7.4, containing 100 mM NaCl. A: OM perme-
abilization. Trace a: untreated bacteria; traces b^d: 0.05, 0.1, 0.3
WM peptide; trace e: sonicated bacteria. B: IM permeabilization.
Trace a: untreated bacteria; trace b: 0.3 WM peptide in the presence
of 1 mM Ca2 ; traces c, e, f : 0.05, 0.1, 0.3 WM peptide; trace d:
0.3 WM peptide in the presence of 1 mM Mg2 ; trace g: sonicated
bacteria. The arrows indicate addition of peptide.
Fig. 2. Scanning electron micrographs of untreated (A and C) and after treatment for 30 min at 37‡C with 2 WM (B) and 5 WM (D) SMAP-29
of E. coli (top) and S. aureus (bottom).
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P. aeruginosa from CF patients, and C. neoformans from pa-
tients with AIDS. All the bacterial strains tested are highly
susceptible to SMAP-29 with MIC values in the 0.12^2 WM
range of concentration (Table 1). The only exception is P.
vulgaris, which is resistant even at 80 WM peptide. Interest-
ingly, SMAP-29 is highly and equally active against antibiotic-
resistant and antibiotic-susceptible clinical isolates of the same
species, e.g. methicillin-resistant vs. methicillin-susceptible S.
aureus. MBC values are in general identical to, or most 2-fold
higher, than the MIC value, indicating that SMAP-29 is bac-
tericidal and not only bacteriostatic (not shown). The peptide
is also active against fungi such as C. albicans, C. neoformans
and R. rubra at MIC values of 0.5^4 WM (Table 1). A com-
parison of the activity of SMAP-29 with that of other
cathelicidin-derived peptides (e.g. BMAP-27, BMAP-28,
PMAP-37 and BMAP-34) [15,16,20], tested with the same
strains under the same conditions, clearly shows that this pep-
tide is the most potent and displays the broadest spectrum of
activity.
3.3. Membrane permeabilization and scanning electron
microscopy
The ability of SMAP-29 to permeabilize the outer (OM)
and inner (IM) membranes of the E. coli ML-35 strain was
tested by real-time spectroscopy, following respectively the
unmasking of the periplasmic L-lactamase and of the cytosolic
L-galactosidase activities to normally non-permeant sub-
strates. In bu¡er A, SMAP-29 at 0.3 WM caused an immediate
permeabilization of the OM with a kinetics of PADAC hy-
drolysis superimposable to that of sonicated bacteria (100%
permeabilization) (Fig. 1A). At 0.05 and 0.1 WM, the rate of
hydrolysis was 49 and 56% that of sonicated bacteria, with a
steady-state attained at respectively 4 and 2 min after peptide
addition. Under the same conditions, a similar extent of IM
permeabilization was obtained, with a slightly longer lag time
(Fig. 1B). IM permeabilization was also tested in bu¡er A
supplemented with Ca2 or Mg2 and in MHB, that was
used for MIC determinations. At 0.3 WM SMAP-29, the pres-
ence of 1.0 mM Ca2 caused an inhibition of approximately
60% in the extent of permeabilization and prolonged the lag
time to attain the steady-state from 0 to 6 min (Fig. 1B). This
inhibition likely depends on the stabilizing e¡ect of Ca2 on
bacterial membranes through interaction with anionic sites on
LPS and competition with the peptide for membrane binding.
Interestingly, when Ca2 was added a couple of minutes after
the peptide no inhibition was observed in IM permeabilization
(not shown). Mg2 ions at 1.0 mM had the only e¡ect of
slightly prolonging the lag time (Fig. 1). An inhibitory e¡ect
was also observed when the assays were performed in MHB.
At 0.5 WM peptide, the rate of IM permeabilization decreased
from 100% in bu¡er A to about 65% in MHB, and the lag
time to attain the steady-state was prolonged from 0 to 9 min
(not shown). This e¡ect might in part depend on the presence
of Ca2 in MHB and, in addition, of polyanionic peptides
derived from the acidic hydrolysate of casein, the major com-
ponent of MHB. These polyanions could complex the cationic
peptides, thereby inhibiting their action, as shown for the
human LL-37 and pig protegrin-1 [21].
The morphological changes induced by SMAP-29, peptide-
treated E. coli ML-35 and S. aureus (MRSA strain) were
examined by scanning electron microscopy. Untreated cells
had a normal, smooth surface (Fig. 2A and C). In contrast,
cells treated for 30 min with SMAP-29 showed surface rough-
ening and blebbing (Fig. 2B and D). In S. aureus, blebs were
more frequent at the division septum and were accompanied
by long, ¢lamentous projections (Fig. 2D). Cells often showed
large holes in their surface and cellular debris likely arising
from cell lysis were also observed. The SEM observations
provide morphological evidence of the potent permeabilizing
activity of SMAP-29. The membrane alterations are similar to
those induced by protegrins [22] and the K-helical peptide
PGYa, designed using a ‘sequence template’ approach [23].
Although expected the permeabilizing activity of SMAP-29
is considerably higher than that of other antimicrobial pep-
tides evaluated under similar conditions, including defensins
[24], the Pro- and Arg-rich peptides Bac5 and Bac7 [25], and
various K-helical peptides such as PMAP-37 [20] and LL-37
[21]. Only BMAP-27 and BMAP-28 from cattle display a
comparable permeabilizing activity [16]. These peptides have
in common with SMAP-29 a hydrophobic C-terminal tail fol-
lowing the conserved Pro-19.
3.4. Hemolytic activity
The potential lytic activity of SMAP-29 on human and
sheep erythrocytes was monitored by following hemoglobin
release from 10% (v/v) cell suspensions. The peptide showed
a signi¢cant hemolytic activity towards human cells, although
at concentrations relatively higher than those e¡ective against
microorganisms. As shown in Fig. 3, SMAP-29 at 4, 20 and
80 WM caused lysis of respectively 4.4, 19.4 and 67% of the
cells. When compared to other peptides with an amphipathic
K-helical conformation, SMAP-29 is more active than magai-
nins and cecropins, that are virtually not hemolytic [26,27],
but less than melittin, a peptide used as a positive control
(Fig. 3). The hemolytic activity of SMAP-29 likely depends
on the balance of several factors that include a high hydro-
phobic moment, a relatively narrow angle subtended by the
cationic residues, and the presence of a highly hydrophobic
Fig. 3. Hemolytic activity of SMAP-29 and melittin on human and
sheep erythrocytes. Hemolysis was evaluated by reading the absorb-
ance at 415 mm of the supernatants of 10% (v/v) suspensions of
sheep (open columns) or human (gray columns) erythrocytes incu-
bated with the indicated peptide concentrations for 30 min at 37‡C.
Results are the mean of three to seven independent experiments
with S.E.M. values ranging from þ 0.1 to þ 3.6.
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region, as previously shown for both natural, such as BMAP-
27 and -28 from cattle and LL-37 from humans [16,19], and
model [28] antimicrobial peptides.
Unlike human, sheep erythrocytes are resistant to SMAP-29
with only 3% lysis even at 80 WM peptide. This likely depends
on di¡erent contents of sphingomyelin (53% of total phospho-
lipids in sheep vs. 25% in human) and phosphatidylcholine
(6 2% of total phospholipids in sheep vs. 31% in human) in
the red blood cells of the two species [29]. Decreased mem-
brane £uidity due to high content of sphingomyelin has been
suggested as a possible explanation for the lower susceptibility
of sheep erythrocytes to several lytic agents [30], including
peptides such as melittin (Fig. 3).
3.5. Conclusions
The above results show that SMAP-29 is a potent and
broad spectrum peptide and suggest that it may be a good
candidate as a lead compound for the development of novel
antiinfective agents. Targets susceptible to this peptide include
antibiotic-resistant clinical isolates that are a major worldwide
problem [22] and P. aeruginosa associated with chronic respi-
ratory in£ammation in CF patients. In addition, SMAP-29 is
also active against fungi that in the last few years have
emerged as a major complication in immunocompromised
patients [31]. On the other hand, the potent antimicrobial
activity of this peptide is associated to toxicity towards mam-
malian cells. This undesirable feature might compromise its
therapeutic use and should be reduced. Dissociation of anti-
microbial and hemolytic activities has in other instances been
obtained by modifying parameters such as hydrophobicity,
amphipathicity and helicity [28], by removing hydrophobic
regions [16,19], or by synthesizing diastereomer peptide ana-
logs [32]. Work is in progress to synthesize SMAP-29 analogs
retaining the antimicrobial, while decreasing hemolytic activ-
ity.
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